Cargando…
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial
INTRODUCTION: The efficacy of a cholinesterase inhibitor, donepezil, in patients with dementia with Lewy bodies (DLB) was investigated to confirm the superiority over placebo in the 12-week, double-blind phase of this phase III study. METHODS: Patients with probable DLB (n = 142) were randomly assig...
Autores principales: | Ikeda, Manabu, Mori, Etsuro, Matsuo, Kazutaka, Nakagawa, Masaki, Kosaka, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338565/ https://www.ncbi.nlm.nih.gov/pubmed/25713599 http://dx.doi.org/10.1186/s13195-014-0083-0 |
Ejemplares similares
-
Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial
por: Mori, Etsuro, et al.
Publicado: (2015) -
Donepezil for Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial
por: Mori, Etsuro, et al.
Publicado: (2012) -
Aphasic mild cognitive impairment in prodromal dementia with Lewy bodies
por: Watanabe, Hiroyuki, et al.
Publicado: (2023) -
Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014) -
Primary Progressive Aphasia as a Prodromal State of Dementia With Lewy Bodies: A Case Report
por: Watanabe, Hiroyuki, et al.
Publicado: (2020)